当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

インデックス付き
  • 索引コペルニクス
  • Google スカラー
  • シェルパ・ロミオ
  • Genamics JournalSeek
  • セーフティライト付き
  • レフシーク
  • ハムダード大学
  • エブスコ アリゾナ州
  • OCLC-WorldCat
  • パブロン
  • ジュネーブ医学教育研究財団
  • ユーロパブ
  • ICMJE
このページをシェアする

抽象的な

Smokeless Tobacco–Countering the Global Epidemic

Jagdish Kaur and Vinayak Prasad

Background: Globally, twelve percent of all deaths among adults aged 30 years and over are attributable to tobacco use. A large proportion of the tobacco attributable disease and deaths in many countries are now due to use of Smokeless tobacco (ST) and this has gone unnoticed in most countries except in a few south Asian economies. However most of the tobacco control strategies have traditionally been directed at smoking forms of tobacco especially cigarettes. The regulation of ST is therefore increasingly posing a major public health challenge, especially in LMIs where high prevalence of ST coexists with limited expertise and resources for regulation.This paper aims to draw attention of relevant stakeholders to the growing epidemic of smokeless tobacco, its impact and issues related to regulation. Methods: A standard literature search was performed using multiple electronic databases to identify peer reviewed articles. The internet and organizational databases were also used to find other types of documents (e.g. books and reports). The reference lists of identified relevant documents were reviewed to find additional sources. Results: The use of smokeless tobacco is prevalent across all WHO regions, with high prevalence (≥ 10%) countries representing about 25% of the global adult population. The use of ST is associated with a wide range of harmful effects on health. Tobacco manufacturers are continuously introducing newer forms of smokeless tobacco products and expanding their user base. The diversity of ST products, information and research gap, industry tactics, promotion as harm reduction product, in addition to lack of resources, technical knowhow and proven regulatory policies have emerged as major challenges to regulate ST globally. Conclusion: The growing epidemic of ST requires sustained and effective public health action. Many countries have tried partial bans on import and sale of ST. Looking at the circumstances and challenges involved in regulating ST, authors call for a more coordinated approach and global and regional consultation to look at appropriate policies and strategies including a complete, comprehensive and transnational ban on ST products to counter this epidemic.